Manipulation of pre-mRNA splicing by antisense oligonucleotides (AOs) offers considerable potential for a number of genetic disorders. One of these is Duchenne muscular dystrophy (DMD), where mutations in the dystrophin gene typically result in premature termination of translation that causes a loss of functional protein. AOs can induce exon skipping such that the mutation is by-passed and the reading frame restored, producing an internally deleted protein similar to that found in the milder Becker muscular dystrophy. To date, this approach has been applied to the mdx mouse model in vitro and in vivo and in human myoblast cultures. Here, we report the application of AO-directed exon skipping to induce dystrophin expression in vitro in a canine model of DMD, golden retriever muscular dystrophy (GRMD). The efficacy of 2 0 -O-methyl phosphorothioate (2OMe), phosphorodiamidate morpholino oligomers (PMOs) and peptide-linked PMOs (PMO-Pep) to induce dystrophin expression was assessed. The 2OMe chemistry was only effective for shortterm induction of corrected transcript and could not induce detectable dystrophin protein. The PMO chemistry generally induced limited exon skipping at only high concentrations; however, a low level of dystrophin protein was produced in treated cells. Use of the PMO-Pep, applied here for the first time to a DMD model, was able to induce high and sustained levels of exon skipping and induced the highest level of dystrophin expression with no apparent adverse effects upon the cells. The induction of dystrophin in the GRMD model offers the potential for further testing of AO delivery regimens in a larger animal model of DMD, in preparation for application in human clinical trials.
Introduction
Duchenne muscular dystrophy (DMD) is a serious X-linked recessive myodegenerative disease, typically caused by nonsense or frame-shifting mutations in the dystrophin gene that result in an absence of functional protein. 1 The precise molecular roles of dystrophin are still being elucidated, but primarily it appears to stabilize the myofibre membrane. An absence of dystrophin compromises the link between the myotube cytoskeleton and the sarcolemmal complex, thereby increasing muscle fragility and leading to a continual degeneration of muscle fibres. Until recently, death occurred owing to cardiac or respiratory failure typically before the third decade, 2 but new treatments and patient management, including glucocorticoid regimens and assisted ventilation, have substantially improved survival. 3, 4 Becker muscular dystrophy (BMD) arises from mutations in the dystrophin gene that typically cause internal in-frame deletions, resulting in a shortened but still partially functional dystrophin protein. In some cases, the internally truncated protein appears to fulfil the role of normal dystrophin so that there are no obvious clinical symptoms and diagnosis may only occur later in life. 5 One proposed strategy for the treatment of DMD is the application of antisense oligonucleotides (AOs) to remove specific exons from the dystrophin mRNA transcript during pre-mRNA processing to either bypass nonsense mutations or to restore the mRNA reading frame around a genomic deletion or duplication. If successfully applied, a DMD gene transcript could be modified to express a BMD-like protein, where manipulation of pre-mRNA splicing could potentially convert a severe DMD phenotype to a milder form of the disease. This approach has been applied to the mdx mouse model, both in vitro and in vivo, 6, 7 and to normal and DMD patient cell lines. 8, 9 In the mdx mouse, AOs were targeted to remove the in-frame exon 23 and hence the mdx nonsense mutation, such that a shortened but semifunctional protein was produced. 6 In studies in human DMD cell lines, AOs were used to target single and multiple exons to restore the dystrophin mRNA reading frame. 10 Here, we report the evaluation of this approach to restore dystrophin expression in the golden retriever muscular dystrophy (GRMD) animal model. Unlike the mdx mouse, which superficially appears clinically normal throughout most of its life, the GRMD dog may be regarded as a more relevant model to study DMD. Affected dogs suffer a fatal, muscle wasting clinical course with fibrosis, contractures and weakness similar to DMD. 11 The similarities in disease progression, and size of the dogs, should be more appropriate in assessing delivery and efficacy of AOs to address dystrophin mutations before moving to clinical trials.
The genetic basis for GRMD is a point mutation in the consensus splice acceptor site in intron 6 of the canine dystrophin gene. 12 This results in the removal of exon 7 from the mRNA transcript causing a frame-shift, such that a prematurely truncated non-functional protein is generated. The development of a treatment for GRMD dogs has relevance to the human disease as exon 7 is within a minor deletion hotspot of the human dystrophin gene. Furthermore, splice site mutations in the human dystrophin genes occur at a frequency of some 10-15% and the consequences of a frame-shift in the mRNA is analogous to the more common genomic deletions encountered in DMD.
We investigated the efficacy of using antisenseinduced exon skipping as a potential treatment for GRMD, where AOs were optimized to target splicing motifs to induce the removal of exons 6 and 8 from the dystrophin mRNA to restore the reading frame. A comparative analysis of the efficacy of 2 0 -O-methyl phosphorothioate (2OMe), phosphorodiamidate morpholino oligomers (PMOs) and peptide-linked PMOs (PMO-Pep) chemistries to induce dystrophin protein was performed in vitro.
AOs have been more commonly used to downregulate gene expression through RNaseH-mediated degradation. 13 However, the chemistries used here do not support RNaseH activity, and in this application rely upon preventing correct assembly of the splicing machinery, through either a displacement mechanism or alteration of essential secondary structure. Although 2OMe and PMO chemistries have been used previously in both mouse and human exon skipping studies, 14, 15 here we report the first use of PMO-Pep to induce modified splicing in the GRMD dystrophin gene transcript. One of the major limitations in evaluating PMOs in cultured cells has been their poor uptake and hence lack of apparent activity. 15 To overcome this problem, PMOs have been conjugated with arginine-rich transport peptides to enhance their cellular uptake. 16 Peptide-conjugated PMOs (PMO-Peps) were compared to non-conjugated PMOs and 2OMeAO of identical sequence for their ability to modify the GRMD transcript. AO chemistries used in this study are shown in Figure 1 . This study provides proof of principle that this AO approach can be used as a therapy for DMD in a more clinically relevant animal model and provides further insight into the most suitable choice of AO chemistry for future studies.
Results

AO design for skipping exons 6 and 8
The removal of either exon 6 or 8 alone from the GRMD dystrophin mRNA transcript will not restore the reading frame disrupted by the loss of exon 7. The simplest solution to restoring the reading frame is the simultaneous removal of exons 6 and 8 such that an internally deleted protein missing 159 amino acids would be produced (Figure 3a) . Another approach would be the removal of exons 8-11. The simpler option of targeting two exons was chosen and 2OMe AOs were used to optimize the target site for AO-induced skipping of exons 6 and 8.
Previous studies in the mdx mouse indicated that the 5 0 donor splice site of exon 23 was the most amenable target to induce 23 exon skipping. 2OMe AOs were designed to the donor splice site for both exon 6 (C6D(+12-13) and C6D(+07-19)) and exon 8 (C8D(+02-15) and C8D(+08-17)) ( Figure 2 ). Transfection of these AO lipoplexes at 300 nM failed to induce exon skipping for either exon as determined by nested PCR analysis (Figure 3b ). Constitutive skipping of the in-frame exon 9 (132 bp) was observed in all samples including untreated and Lipofectamine 2000 (L2K)-only treated cells and has been reported elsewhere. 17 Another series of 2OMe AOs were subsequently designed to target the 3 0 acceptor splice sites of intron 5 (C6A(À14+06) and C6A(À10+10)) and intron 7 (C8A(À10+10) and C8A(À04+18)), respectively ( Figure 2) . Although no exon 6 skipping was observed, C8A(À04+18) was able to induce efficient skipping of exon 8 (185 bp) from the mRNA transcript at 300 nM (Figure 3b ), whereas C8A(À10+10) was found to be ineffective under these conditions. The removal of exon 8 was always accompanied by the removal of the in-frame exon 9, as confirmed by DNA sequencing analysis (data not shown). This was further confirmed by amplification across exons 1-9, which indicated that transcripts skipping exon 8 alone could not be detected as only full-length product was observed ( Figure 3c ).
As targeting of exon 6 consensus splice sites had failed to induce exon skipping, additional 2OMe AOs were designed to target putative exon splicing enhancer (ESE) elements identified using ESE Finder version 2.0 (http:// rulai.cshl.edu/tools/ESE/). 18 Targeting a putative exon 6 Figure 3b ). Most transcripts missing exon 6 also had exon 9 absent. Since transcripts missing exon 9 were detected in untreated or sham-treated cultures, it is assumed that the removal of exon 9 was a constitutive event and was not influenced by the AO. However, unlike the induced skipping of exons 8 and 9, the removal of exon 6 alone could be observed in amplification from exons 1 to 9 ( Figure 3c ). To determine the efficacy of these AOs, C8A(À04+18) and C6A(+69+91) were transfected at a series of concentrations from 20 to 600 nM. For both C6A(+69+91) (Figure 3d ) and C8A(À04+18) (Figure 3e ), removal of exons 6 and 8 was consistent and pronounced to 50 nM with lower levels of exon skipping still observed at 20 nM. This induced skipping also resulted in reduced levels of the full-length transcript at higher AO concentrations.
Exons 6 and 8 removal to restore mRNA reading frame
Having designed AOs to induce the removal of exons 6 and 8, PMO and PMO-Peps of identical sequence were synthesized. Canine myoblasts were co-transfected over a range of concentrations using equal amounts of C6A(+69+91) and C8A(À04+18) for each AO chemistry to allow a comparison of AO efficacy. Transfection with 2OMe AOs was limited by AO:lipoplex-associated toxicity at higher concentrations. A delivery agent for 2OMe AO transfection was essential as uncomplexed 2OMe AOs, even at 10 mM concentration, induced no detectable exon skipping (data not shown). The uncharged PMO and PMO-Peps could not be complexed with the cationic liposome, but were transfected alone and showed no obvious deleterious effects on the cultured cells at any concentration tested. Three days after transfection, simultaneous removal of both exons from the mRNA transcript was observed for all AOs tested, with no induced skipping in untreated samples ( Figure 4 ). As anticipated, exon 9 was also removed so that the AO-induced dystrophin transcript was missing exons 6-9 (466 bp). The precise splicing of exons 5-10 was confirmed by sequence analysis (Figure 4d ) and represents an in-frame transcript, which should be translated into a semi-functional protein. RNA analysis of downstream dystrophin mRNA did not show any aberrant splicing, indicating that induced exon skipping was specific to the region targeted (data not shown).
Removal of either exon 6 or 8/9 from the mRNA transcript alone was also observed for all AO chemistries ( Figure 4 ). Transfection with 2OMe AO lipoplexes induced removal of exons 6-9 at 20 nM, albeit weakly ( Figure 4a ). In contrast, uncomplexed PMO only induced high levels of exons 6-9 skipping at 20 mM with weak exon skipping at 10 mM ( Figure 4b ). However, the use of the conjugated peptide improved exon skipping, such that high levels of exons 6-9 removal were observed at concentrations of 300 nM, with removal of either exons 6 or 8/9 alone also observed at 50 nM ( Figure 4c ). Significantly, essentially no product representing the intact dystrophin transcript was detected in those cells transfected at or above 300 nM ( Figure 4c ).
Persistence of in-frame transcript
Although each of the 2OMe, PMO and PMO-Pep combination of AOs had induced the in-frame transcript, we sought to determine the persistence of induced exon skipping for each chemistry. PMO and PMO-Pep were transfected at 10, 5 and 1 mM and the 2OMe AO lipoplexes at 300, 150 and 75 nM ( Figure 5 ). RNA was extracted 1, 4, 7 and 10 days following a single transfection and reverse transcription-polymerase chain reaction (RT-PCR) analysis performed. 2OMe AO lipoplexes initially induced high levels of exon skipping, but this rapidly declined by day 7 and was only detected at low levels on day 10 at the highest transfection concentration ( Figure 5d ). It should be noted that this coincided with a reduction in cell number from day 7 onwards, presumably arising from AO lipoplex-associated toxicity. Transfection with PMO-induced negligible levels of transcript missing exons 6-9 from days 1 to 10, although low levels of transcripts with exon 6/9 (636 bp) or 8/9 (624 bp) exclusion were present ( Figure  5 ). Transfection with PMO-Peps induced high levels of exons 6-9 skipping at all time-points, and by day 10, PMO-Peps were the only compounds to have sustained exon skipping ( Figure 5d ).
Dystrophin expression in treated cells
Western blot analysis was performed on protein extracted from AO-transfected myotube cultures to confirm the proof of concept that the restoration of the in-frame dystrophin mRNA transcript would result in the production of dystrophin protein and provide a further comparison of the efficacy of the AO chemistries in restoring dystrophin production. Following 14 days of differentiation, myotube cultures were transfected with either 20 mM of PMO-Pep, 20 mM PMO or 1 mM 2OMe AO 
Discussion
The presence of dystrophin-positive revertant fibres in dystrophic tissue is evidence of a low level of endogenous exon skipping, whereby the disease-causing mutation is excluded. These revertant fibres occur at a frequency too low to have any clinical benefit. However, well-documented cases of variably affected BMD patients, in some cases with major genomic deletions and very mild phenotypes, are evidence that the production of some shortened in-frame deleted dystrophin proteins can have a major benefit. To date, studies in the mdx mouse and in DMD patient cell lines have demonstrated the use of AOs to manipulate pre-mRNA splicing to induce shortened in-frame transcripts to produce substantial amounts of dystrophin protein. 9, 19 In this study, we report the first use of AOs to induce in vitro production of dystrophin in a canine model of DMD.
It has been our experience that one of the more crucial aspects of AO-induced exon skipping is the selection of the target and design of AOs. The removal of exons from the pre-mRNA is presumed to be caused by steric interference by the AOs preventing the correct assembly of the spliceosome. Previous studies in the mdx mouse indicated only AOs targeted to the 5 0 donor splice site of exon 23 induced efficient and consistent skipping. 6 The targeting of the 3 0 splice site of intron 22 had no effect on the mouse dystrophin pre-mRNA splicing, whereas in the present study, targeting the 5 0 donor splice sites did not induce skipping of either exon 6 or 8. Although the first series of AOs designed to the GRMD dystrophin pre-mRNA were targeting a crucial domain involved in splicing, it is possible that these AOs were not able to overcome secondary structures in the pre-mRNA and 20 was used to predict areas of accessibility, but these programs may be of limited value, as multiple RNA structures are predicted and will vary depending on the input of target sequence. In contrast to the amenable exon 23 donor splice site target in the mdx model, targeting the 3 0 acceptor splice site of canine dystrophin intron 7 was very effective in inducing exclusion of exon 8 from the mature mRNA. However, exon 8 removal was dependent on precise targeting where only one of two AOs directed to this splice site was able to induce exon skipping (Figure 3b 18 which predicts potential binding sites for serine/arginine-rich (SR) proteins, a family of structurally related and highly conserved splicing factors, characterized by RNA recognition motifs (RRM) and an arginine/serine (RS) domain. 21 The RRM domain confers exon specificity and recognition through binding to specific RNA sequences. The RS domain is thought to either promote exon definition by recruiting splicing factors and/or by inhibiting the actions of nearby silencer elements. 22 In general, ESE Finder predicts potential ESEs within exons, with estimates based on homology to consensus sequences. This program identified several motifs within exon 6, one of which was targeted by C6A(+69+91) to induce skipping of that exon. It is assumed that this AO binding disrupted essential RRM base pairing with exon 6, thereby preventing binding of some SR proteins and retention of exon 6 in the mature mRNA. Interestingly, the AO C8A(À04+18) that spans the intron 7/exon 8 junction also targeted a region identified as binding potential ESEs. This may give an indication as to why the C8A(À10+10) AO could not induce skipping, as despite overlap in the targeted sequence, this AO may not displace enough of the SR protein binding to disrupt splicing. However, the exon 6 AOs targeted to the acceptor and donor sites, which did not induce exon skipping, also targeted putative SR protein binding regions. Thus, it appears that while prediction of ESE sites may provide potential targets for AOs, empirical testing will still remain necessary as there is no obvious motif that will guarantee exon exclusion after AO targeting. Compounding the limitations of AO target prediction is that current ESE programs are modelled on human SR proteins, and so may be less relevant when designing AOs for other species. Even when predicting AO binding sites in the human dystrophin gene transcript, it is our experience that not all identified potential ESEs will induce exon skipping when targeted with AOs (unpublished data).
The nonspecific exclusion of exon 9 was observed in about 50% of canine dystrophin transcripts from untreated cells and has also been observed in human and mouse muscle. 17 This constitutive skipping is thought to be owing to the 3 0 end of exon 9 reflecting the consensus sequence of an intronic 3 0 splice site, such that it is 'recognized' as an intron and removed from the mRNA transcript. 17 As such, it was not surprising to observe frequent removal of exon 9 in dystrophin transcripts missing exon 6 or 8, or both. The removal of exon 9 from the mature mRNA will not disrupt the reading frame and hence should not have a detrimental effect on dystrophin expression. Perhaps reflecting the close co-ordination of exons 8 and 9 processing, the AO-induced removal of exon 8 was always accompanied by the loss of exon 9, suggesting that the splicing of exons 8 and 9 are inextricably linked, whereas this was not the case for exon 6 skipping. The sizes of the introns involved may also influence splicing patterns, as intron 7 is approximately 97 kb, whereas intron 8 is only 1% of this length and intron 9 is over 25 kb in length. This feature of a single AO removing two exons has also been observed in studies in the mdx mouse, where exons 22 and 23 removal was frequently seen when AOs were targeted to exon 23. 23 Similarly, a high dose of AO targeted to exon 46 occasionally induced removal of both exons 45 and 46 from human dystrophin transcripts. 15 Nested RT-PCR analysis was used to compare the efficacies of the different AO chemistries as the GRMD dystrophin mRNA level is too low to detect by Northern analysis 12 and real-time PCR analysis is unsuitable for quantitation of multiple related transcripts. Although nested RT-PCR does not allow for the precise calculation of the levels of exon skipping observed, the comparison in efficacy can be considered semi-quantitative as amplification conditions remained constant throughout the study. The apparent efficacy of exon skipping using 2OMe C6A(+69+91) and C8A(À04+18) at low lipoplex doses (to 20 nM) was very high (Figure 4a ). This multiple exon skipping is most remarkable when one considers that all four exons removed from the transcript, one by a splice site mutation and three through the AO action, span a considerable length of the pre-mRNA.
In contrast, although skipping of exons 6 and 8 was observed with the PMOs of equivalent sequence, it was only observed after transfection at higher AO concentrations ( Figure 4b ). As PMOs are uncharged, they cannot be complexed with cationic liposomes and presumably rely on passive diffusion through the cellular membrane. It has become apparent that this poor cellular uptake is the cause of low levels of exon skipping rather than an inability of the PMO to exert its antisense effect. In mdx mouse studies, the use of a sense 'leash' with a charged phosphodiester or phosphorothioate backbone enabled the PMO to be complexed with liposome and induce levels of exon skipping at relatively low concentrations (B10 nM).
14 Although this greatly enhanced the PMOinduced exon skipping, this complex preparation could be difficult to apply in a clinical setting.
The conjugation of a transport peptide facilitated nuclear uptake, with high levels of induced in-frame transcript demonstrating that when the PMO can be effectively transported into the cell, it exerts potent and sustained antisense activity. Additionally, in terms of a clinical application, it would be preferable to use a chemistry that did not require a transfection agent, as a limitation of using cationic liposomes as a carrier is associated toxicity and aggregation with serum proteins in vivo. 24 This was demonstrated by moderate cell death observed 7 days after transfection with 600 nM of 2OMe A study of the persistence of the in-frame transcript missing exons 6-9 indicated that while the 2OMe AOs were initially very effective, the shortened transcript declined rapidly. Although there was an observed increase in cell death over time, this toxicity was not enough to account for the decline in induced transcript and is most likely owing to metabolism and decay of the 2OMe AO. This pattern of induced exon skipping is similar to that reported in the mdx mouse, where shortened transcripts were observed on day 1 and only low amounts were present 10 days following in vitro AO transfection. 23 However, there was still some skipping of either exon 6 or 8 alone at day 10, suggesting that some 2OMe AO must still be present, as these out-of-frame transcripts should be rapidly turned over owing to nonsense-mediated decay.
Given that the PMOs are taken up poorly in vitro, it was not surprising that almost negligible exon skipping was observed for all time points. However, as uncomplexed PMOs rely on passive diffusion to enter the cell, it was hypothesized that the level of induced exon skipping would increase over time, although this was not the case. This was in stark contrast to the PMO-Pep, where at the same PMO concentration, the use of a conjugated transport peptide overcame limitations in the in vitro delivery to induce high levels of skipping at all time points. This suggests that once the PMO is in the cell, it remains more stable than the 2OMe chemistry and hence can exert more sustained antisense activity, although this activity may be enhanced by an absence of toxicity. Additionally, use of a PMO:leash lipoplex in the mdx mouse resulted in increased persistence of exon 23 removal in comparison to 2OMe AO lipoplex, indicating that the PMO chemistry appears to exert its antisense effect for longer. 14 The ability of the PMO-Pep to be delivered as a simple formulation also reduces potential problems associated with carrier agents and could simplify clinical application. Thus, despite the 2OMe AO chemistry being able to induce exon skipping at a lower concentration for a short period (20 nM) compared to the PMO-Pep (300 nM), the lack of adverse effects of the PMO allows higher doses to be used, and hence induce maximal, sustained exon skipping.
One limitation of using GRMD primary myoblasts is the poor ability of the cells to differentiate in cell culture. This in turn presents difficulties in studying dystrophin protein, which is expressed late in the differentiation process and accounts for only 0.002% of total muscle protein. Despite this, near full-length dystrophin protein could be detected by Western blot using high-dose transfection of uncomplexed PMO and PMO-Pep ( Figure  6a) . A direct comparison of AO chemistries at the same concentration could not be made, as 2OMe AO lipoplex concentrations in excess of 1 mM induced excessive cell death.
It was somewhat surprising that the PMOs alone were able to induce any dystrophin protein; however, the level of protein present is barely detectable. The level of exons 6 and 8 skipping at the time of protein extraction was very low, but it seems likely that exposure of the PMO over time allowed some shortened in-frame transcript to accumulate and be translated (Figure 6b ). Although the 2OMe AO lipoplex-treated cells also showed similar levels of exon skipping at the time protein was harvested, there were insufficient cells expressing dystrophin to allow detection by Western blotting. The PMO-Peps transfect efficiently at all stages of cell culture and maintained a high level of induced in-frame transcripts over time. Given that the total protein loaded from treated cultures was higher than for normal cultures, as estimated by b-spectrin analysis, the level of induced dystrophin is significantly lower. This was not unexpected as the relative level of dystrophin mRNA in GRMD compared to normal cells lines is vastly reduced. A comparison between GRMD and normal canine dystrophin mRNA levels indicated that GRMD mRNA was too low to be detected by Northern analysis, 12, 25 presumably owing to the rapid nonsensemediated decay of the out-of-frame GRMD transcript. Thus, although in normal cell lines all of the dystrophin transcripts have the potential to be translated into protein, only those GRMD transcripts that are corrected by AO-mediated intervention will have the potential to be translated into an internally deleted dystrophin protein. Coupled with the difficulties in using GRMD cultures in vitro, this may contribute to the low level of induced dystrophin protein in comparison to normal dystrophin levels. Most importantly, the proof of concept that dystrophin protein can be induced in the GRMD model using this AO-based approach facilitates the testing of AOs in a highly relevant animal model of DMD. Future application to the canine model in vivo will provide information about the AO treatment regimens necessary to induce a functional benefit in a larger animal, as well as demonstrate any potential adverse effects. This in turn should give a better indication of the potential for success of this AO approach in human clinical trials as well as provide a platform for the testing of new AO chemistries and delivery techniques as they become available.
The disease progression and clinical similarities of the GRMD model to the human disease, as well as the larger size, makes affected dogs excellent models for preliminary studies before clinical trials. In addition, the location of the canine gene lesion involves an exon involved in the minor deletion hotspot in the human dystrophin gene. Removal of exon 8 alone would restore the reading frame of approximately 4.5% of DMD-deletion patients. 26 In-frame deletions in this region would be expected to produce a functional dystrophin protein, as evidenced by a report describing a very mild BMD patient with a 3-9 deletion, who was only diagnosed at the age of 65 years. 5 This work is a proof-of-principle study to develop AOs that could overcome the GRMD mutation and induce dystrophin expression. Although 2OMe AOs were more efficient at lower concentrations in inducing the in-frame dystrophin transcript, its limitations include the use of a delivery agent and the rapid decline in exon skipping levels over time, suggesting that this chemistry may not be ideal. In comparison, uncomplexed PMOs could be used at much higher doses, and in doing so, have been shown to be able to induce dystrophin protein in vitro in the GRMD model. The use of a conjugated transport peptide overcame the problem of poor transfection efficiency of PMOs and subsequently showed Restoration of dystrophin in canine model of DMD G McClorey et al that PMO-Peps could induce sustained and significant levels of exon skipping. We propose that PMOs and in particular PMO-Peps may be the most suitable chemistry available for the manipulation of exon splicing to address dystrophin mutations.
Materials and methods
AOs and primers
The nomenclature and sequences of 2OMe AO, PMOs and PMO-Pep are shown in Figure 2 . 2OMe AOs were synthesized in-house on an Expedite 8909 Nucleic Acid Synthesizer using the 1 mmol thioate synthesis protocol with 2 0 -O-methyl cyanoethyl phosphoramidites and support columns supplied by Glen Research, Sterling, USA. Upon completion of synthesis, the AO was deprotected and cleaved from the column support with NH 4 OH. AOs were desalted using NAP-10 columns under sterile conditions. All 2OMe AOs have a phosphorothioate backbone with a 2 0 -O-methyl ribose modification. AOs were designed complementary to target sequences for canine dystrophin exons 6 and 8 and their respective introns (Figure 2 ). Nomenclature system for the AOs was based on that used in the mdx mouse, 23 where C indicates canine, # refers to exon and (#/#) refers to the annealing co-ordinates relevant to the intron/exon boundary. PMOs and PMO-Pep conjugates of identical sequence to the optimized 2OMe AOs were synthesized by AVI BioPharma (Corvallis, OR, USA). Primers for RT-PCR analysis were synthesized by Geneworks (Adelaide, Australia).
Cell culture and AO transfection
Muscle biopsies were obtained from affected pups within the GRMD colony maintained at Murdoch University, West Australia. Primary myoblasts were isolated by enzymatic dissociation using a Dulbecco's modified Eagle's medium (DMEM) solution containing 2.4 U/ml dispase (Roche Diagnostics, NSW, Australia), 1% (w:v) type II collagenase (Roche) at 2 ml/g of tissue incubated at 371C for 45 min. Myoblasts were proliferated at 371C, 5% CO 2 in Hams F-10 media (Invitrogen, Melbourne, Australia) supplemented with 20% fetal bovine serum (Invitrogen), 0.5% chick embryo extract (US Biological, MA, USA), 10 U/ml penicillin (Invitrogen), 10 mg/ml streptomycin (Invitrogen) and 250 ng/ml amphotericin B (Sigma, Castle Hill, Australia). Myoblasts were then plated at 2 Â 10 4 cells/well into 24-well plates for RNA analysis or at 1 Â 10 6 cells into a 25 cm 2 flasks for protein analysis. Plates were coated with 50 mg/ml poly-D-lysine (Sigma) and 100 mg/ml Matrigel (Becton Dickinson, NSW, Australia) and flasks with Matrigel alone. Myoblasts were differentiated in DMEM supplemented with 5% horse serum (Invitrogen) for 3 days for RNA studies and 14 days for protein studies before transfection. 2OMe AOs were transfected in Opti-MEM using L2K at a 1:1 (wt:wt) AO:lipoplex ratio according to the manufacturer's instructions (Invitrogen), whereas PMO and PMO-Pep conjugates had no delivery agent and were transfected in DMEM with 5% horse serum.
RNA extraction and RT-PCR analysis
RNA was extracted from pooled duplicate wells of AOtransfected cells using Trizol (Invitrogen) at time points specified. RT-PCR was performed with 100 ng of total RNA for 35 cycles of amplification using 1 U of Superscript III (Invitrogen) in a 12.5 ml reaction volume. Primers amplifying from exons 1 to 10 (CanDys1Fa, 5 0 -catcagagaaaaacgaatagg-3 0 and CanDys10Ra, 5 0 -aatctctccttgggcttgcag-3 0 ) were used at 941C for 30 s, 551C annealing for 1 min and 721C extension for 2 min. A 1 ml sample from this reaction was then used as the template for 30 cycles of secondary PCR amplification using 0.5 U of AmpliTaq Gold (Applied Biosystems, CA, USA). Nested PCR was performed using primers for exons 1-10 (CanDys1Fb, 5 0 -gtgggaagaagtagaggactg-3 0 and CanDys10Rb 5 0 -ctcagctgaaagaagccacga-3 0 ) under cycling conditions described above. Products were then electrophoresed on a 2% Tris-acetate-ethylenediamine tetraacetic acid (TAE) agarose gel, with products of interest purified using UltraClean spin columns (MoBio Laboratories, CA, USA) and then sequenced on an Applied Biosystems 377 automated sequencer using BigDye V3.1 terminator chemistry (Applied Biosystems).
Protein extraction and Western blotting
Protein was extracted from AO-treated T-25 flasks 7 days following transfection. Cells were trypsinized, pelleted by centrifugation and resuspended in 300 ml of protein extraction buffer (125 mM Tris-HCl, pH 8.8, 4% (w:v) SDS, 40% (v:v) glycerol, 0.5 mM phenylmethyl-sulphonyl fluoride and 0.5 ml protease inhibitors cocktail (Sigma)), sonicated and heated to 951C for 5 min. Before protein extraction, 10% of cell suspension was used for RNA extraction and subsequent exon skipping analysis. Fifty microlitres of extracted protein volume was loaded onto a denaturing 3-10% gel with a 3% stacking gel and electrophoresed at 30 mA for 5 h at room temperature. As a positive control, 10 and 30 ml of protein extracted from 14-day myoblast cultures from unaffected golden retriever littermates was used. Fractionated proteins were then electroblotted overnight at 290 mA at 181C onto nitrocellulose membrane (Amersham, NJ, USA). DYS 1 (Novacastra Laboratories, Newcastle-Upon Tyne, UK) antibody (1:100) was used to probe for the presence of canine dystrophin and NCL-SPEC2 (Novacastra) antibody (1:100) for b-spectrin. Chemiluminescent detection was performed using Western Breeze (Invitrogen) according to the manufacturer's instructions. Membranes were then exposed to Hyperfilm (Amersham) for visualization.
